|
Ananda Pharma PLC on Monday said the last patient has received their final MRX1 dose in the phase one pharmacokinetic study. Ananda is a London-based biopharmaceutical company that develops regulatory-approved cannabinoid medicines to treat complex, chronic conditions. MRX1 is the company’s lead cannabidiol drug candidate. Ananda reported that the first patient had been dosed back in July. The PK study is taking place at a clinical site in Melbourne, Australia, with the database now locked. Ananda said final readouts are on track for delivery in the first quarter of next year. The company added that it expects to be in a position to report on the safety and tolerability of the drug in the fourth quarter of this year. Ananda noted that data from this trial will be used for Federal Drug Administration filings. Shares in Ananda were unchanged at 0.275 pence on Monday afternoon on London’s Aquis Exchange. ‘Reaching Last Participant, Last Dose is an important milestone in our MRX1 development programme. I am particularly pleased that half the participants in the study were female. It is crucial for our strategy to advance MRX1 CBD through the regulatory pathway for the treatment of pain associated with endometriosis that we understand how MRX1 CBD acts in the female body,’ said Chief Executive Melissa Sturgess. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
